German Cancer Research Center   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Heidelberg Germany (1964)

Organization Overview

First Clinical Trial
1999
NCT00717210
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Deutsches Krebsforschungszentrum | Deutsches Krebsforschungszentrum (DKFZ) | German Cancer Research Center | German Cancer Research Center Germany | German Canecr Research Center, Heidelberg, and Mannheim University Hospital, Neurology, Mannheim

Active Ingredients

Drugs in Phase 4 Trials (1)

human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)

Drugs in Phase 3 Trials (1)

temozolomide (temodar) (1 trial)

Drugs in Phase 2 Trials (36)

acetylcysteine (mucomyst) (1 trial)

afatinib (gilotrif) (1 trial)

alectinib (alecensa) (2 trials)

apg101 (1 trial)

atezolizumab (Tecentriq) (4 trials)

autologous natural killer cells (1 trial)

bendamustine (treanda) (1 trial)

binimetinib (mektovi) (1 trial)

bortezomib (velcade) (1 trial)

cobimetinib (cotellic) (1 trial)

doxorubicin (Doxil) (1 trial)

encorafenib (braftovi) (1 trial)

entinostat (1 trial)

etoposide (vepesid) (1 trial)

flecainide (tambocor) (1 trial)

Ga 68 PSMA-11 (Illuccix) (1 trial)

gdc-0077 (1 trial)

idasanutlin (1 trial)

ifosfamide (ifex) (1 trial)

imiquimod (aldara) (2 trials)

ipatasertib (2 trials)

nivolumab (opdivo) (2 trials)

olaparib (lynparza) (1 trial)

palbociclib (ibrance) (1 trial)

pazopanib (votrient) (1 trial)

pertuzumab (perjeta) (2 trials)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (1 trial)

sacituzumab govitecan (Trodelvy) (1 trial)

sargramostim (leukine) (1 trial)

talazoparib (talzenna) (1 trial)

temsirolimus (torisel) (1 trial)

tocilizumab (actemra) (1 trial)

trastuzumab (herceptin) (2 trials)

vemurafenib (zelboraf) (1 trial)

vismodegib (erivedge) (1 trial)

Drugs in Phase 1 Trials (13)

avelumab (bavencio) (1 trial)

cobicistat (stribild) (1 trial)

donor-derived cd34+ hsc with crispr/cas9-mediated cd33 deletion (1 trial)

gemtuzumab ozogamicin (mylotarg) (1 trial)

h3k27m peptide vaccine (1 trial)

idh1 peptide vaccine (1 trial)

idh1r132h (1 trial)

ipilimumab (yervoy) (1 trial)

maraviroc (selzentry) (1 trial)

montanide isa51 (1 trial)

panhpvax (1 trial)

psmaxcd3 (1 trial)

re-activated t cells (1 trial)

Drugs in Other Trials (1)

betahistine mesilate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 3)

Carcinoma, Bronchogenic (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 1)

Digestive System Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 1)

Hodgkin Disease (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lung Neoplasms (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Oligodendroglioma (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Sarcoma (Phase 2)

Uterine Cervical Neoplasms (Phase 4)

Virus Diseases (Phase 2)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 52